치료 저항성 우울증(TRD) 치료 시장 : 규모, 점유율, 성장, 업계 분석, 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of treatment-resistant depression (TRD) treatment Market

The global treatment-resistant depression (TRD) treatment market is experiencing notable growth due to the rising burden of major depressive disorders and the need for advanced therapeutic solutions. The market was valued at USD 2.40 billion in 2025 and is projected to grow to USD 2.67 billion in 2026, reaching USD 6.15 billion by 2034, expanding at a CAGR of 11.00% during the forecast period. North America dominated the market with a 53.51% share in 2025, driven by strong healthcare infrastructure and increasing adoption of innovative therapies.

Treatment-resistant depression occurs when patients fail to respond adequately to at least two antidepressant therapies. It is associated with complex biological and psychological factors such as neurotransmitter dysfunction, inflammatory responses, and abnormal neural activity. The growing need to address severe depression cases and reduce suicide risks is significantly contributing to market expansion.

Market Dynamics

Growth Drivers

The primary driver of market growth is the increasing prevalence of treatment-resistant depression globally. A significant portion of patients with major depressive disorder do not respond to conventional therapies, creating a strong demand for advanced treatment options.

Another key factor is the rising investment in research and development by pharmaceutical companies. Leading players are actively developing innovative therapies, including rapid-acting antidepressants and novel drug classes, to address unmet clinical needs. Increased clinical trials and regulatory approvals are accelerating the availability of effective treatments.

Additionally, the growing awareness of mental health and reduction in social stigma are encouraging more patients to seek treatment. Improved healthcare access and awareness campaigns in emerging economies are further supporting market growth.

Market Restraints

Despite positive growth trends, the market faces challenges such as the lack of standardized treatment guidelines for managing TRD. Variability in diagnosis and treatment approaches often leads to inconsistent patient outcomes.

Moreover, limited therapeutic options and treatment discontinuation rates hinder market expansion. Patients often drop out due to delayed drug effectiveness or inadequate results, affecting long-term treatment adoption.

Market Trends

A major trend in the market is the shift from traditional oral antidepressants to alternative routes of administration, such as intranasal and intravenous therapies. These methods offer faster onset of action, with some treatments showing improvements within hours instead of weeks.

The increasing adoption of NMDA receptor antagonists, such as esketamine, is another significant trend. These therapies provide rapid symptom relief and are gaining traction among healthcare providers.

Furthermore, the market is witnessing growing innovation in drug development pipelines, with companies focusing on personalized medicine and targeted therapies to improve treatment outcomes.

Segmentation Analysis

By drug type, the antidepressants segment dominates the market due to widespread use of SSRIs and SNRIs as first-line treatments. These drugs remain the most commonly prescribed options for managing depression.

The NMDA segment is expected to grow at the fastest rate, driven by increasing adoption of innovative therapies such as esketamine nasal spray and strong clinical pipelines targeting rapid symptom relief.

By distribution channel, the hospital pharmacies segment holds the largest share, as most TRD treatments require medical supervision and prescription-based dispensing.

Retail pharmacies also contribute significantly due to accessibility, while the online pharmacies segment is expected to witness the fastest growth, supported by increasing digitalization and patient convenience.

Regional Insights

North America leads the global market, with a value of USD 1.29 billion in 2025 and USD 1.43 billion in 2026, driven by high disease prevalence, strong reimbursement systems, and continuous drug approvals.

Europe holds the second-largest share, supported by increasing R&D investments and favorable regulatory initiatives aimed at improving mental healthcare.

Asia Pacific is expected to grow at a steady pace due to rising awareness, improving healthcare infrastructure, and increasing diagnosis rates. Countries such as China and India are witnessing growing demand for advanced psychiatric treatments.

The rest of the world is projected to grow moderately, supported by rising healthcare expenditure and gradual improvements in mental health services.

Competitive Landscape

The market is highly competitive, with key players such as Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline plc, Janssen Global Services, and AbbVie Inc. leading the industry. These companies are focusing on research collaborations, clinical trials, and product innovation to strengthen their market presence.

Recent developments include multiple Phase II and Phase III clinical trials, new drug approvals, and increased investments in innovative therapies targeting treatment-resistant depression.

Conclusion

The treatment-resistant depression treatment market is poised for significant growth, driven by increasing disease prevalence, advancements in drug development, and rising awareness of mental health. Although challenges such as lack of standardized guidelines and limited treatment options persist, ongoing innovation and strong R&D investments are expected to transform the market landscape and improve patient outcomes in the coming years.

Segmentation By Drug Type

• N-methyl-D-aspartate (NMDA)
• Antidepressants
• Antipsychotics
• Others

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

By Geography

• North America (U.S. and Canada)
• Europe (Germany, U.K., France, Italy, Spain, and the Rest of Europe)
• Asia Pacific (China, India, Japan, Australia, and the Rest of Asia Pacific)
• Rest of the World

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Treatment-Resistant Depression, By Key Countries/Regions, 2025
• 4.2. Overview of Current Advances in R&D for Antipsychotic Drugs
• 4.3. Pipeline Analysis: Key Players
• 4.4. Key Industry Developments, Mergers, Acquisitions, Etc.
• 4.5. Impact of COVID-19 on Market

5. Global Treatment-Resistant Depression Treatment Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Type
  • 5.1.1. N-methyl-D-aspartate (NMDA)
  • 5.1.2. Antidepressants
  • 5.1.3. Antipsychotics
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.2.1. Hospital Pharmacies
  • 5.2.2. Drug Stores & Retail Pharmacies
  • 5.2.3. Online Pharmacies
• 5.3. Market Analysis, Insights and Forecast - By Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Rest of the World

6. North America Treatment-Resistant Depression Treatment Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Type
  • 6.1.1. N-methyl-D-aspartate (NMDA)
  • 6.1.2. Antidepressants
  • 6.1.3. Antipsychotics
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.2.1. Hospital Pharmacies
  • 6.2.2. Drug Stores & Retail Pharmacies
  • 6.2.3. Online Pharmacies
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Treatment-Resistant Depression Treatment Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Type
  • 7.1.1. N-methyl-D-aspartate (NMDA)
  • 7.1.2. Antidepressants
  • 7.1.3. Antipsychotics
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.2.1. Hospital Pharmacies
  • 7.2.2. Drug Stores & Retail Pharmacies
  • 7.2.3. Online Pharmacies
• 7.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.3.1. Germany
  • 7.3.2. U.K.
  • 7.3.3. France
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Rest of Europe

8. Asia Pacific Treatment-Resistant Depression Treatment Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Type
  • 8.1.1. N-methyl-D-aspartate (NMDA)
  • 8.1.2. Antidepressants
  • 8.1.3. Antipsychotics
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.2.1. Hospital Pharmacies
  • 8.2.2. Drug Stores & Retail Pharmacies
  • 8.2.3. Online Pharmacies
• 8.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.3.1. China
  • 8.3.2. India
  • 8.3.3. Japan
  • 8.3.4. Australia
  • 8.3.5. Rest of Asia Pacific

9. Rest of the World Treatment-Resistant Depression Treatment Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Type
  • 9.1.1. N-methyl-D-aspartate (NMDA)
  • 9.1.2. Antidepressants
  • 9.1.3. Antipsychotics
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.2.1. Hospital Pharmacies
  • 9.2.2. Drug Stores & Retail Pharmacies
  • 9.2.3. Online Pharmacies

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. Eli Lilly and Company
    • 10.2.1.1. Overview
    • 10.2.1.2. Products
    • 10.2.1.3. SWOT Analysis
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. Strategies
    • 10.2.1.6. Financials (Based on Availability)
  • 10.2.2. GlaxoSmithKline
    • 10.2.2.1. Overview
    • 10.2.2.2. Products
    • 10.2.2.3. SWOT Analysis
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. Strategies
    • 10.2.2.6. Financials (Based on Availability)
  • 10.2.3. Pfizer Inc.
    • 10.2.3.1. Overview
    • 10.2.3.2. Products
    • 10.2.3.3. SWOT Analysis
    • 10.2.3.4. Recent Developments
    • 10.2.3.5. Strategies
    • 10.2.3.6. Financials (Based on Availability)
  • 10.2.4. Janssen Pharmaceuticals
    • 10.2.4.1. Overview
    • 10.2.4.2. Products
    • 10.2.4.3. SWOT Analysis
    • 10.2.4.4. Recent Developments
    • 10.2.4.5. Strategies
    • 10.2.4.6. Financials (Based on Availability)
  • 10.2.5. AbbVie Inc.
    • 10.2.5.1. Overview
    • 10.2.5.2. Products
    • 10.2.5.3. SWOT Analysis
    • 10.2.5.4. Recent Developments
    • 10.2.5.5. Strategies
    • 10.2.5.6. Financials (Based on Availability)
  • 10.2.6. AstraZeneca
    • 10.2.6.1. Overview
    • 10.2.6.2. Products
    • 10.2.6.3. SWOT Analysis
    • 10.2.6.4. Recent Developments
    • 10.2.6.5. Strategies
    • 10.2.6.6. Financials (Based on Availability)
  • 10.2.7. H. Lundbeck
    • 10.2.7.1. Overview
    • 10.2.7.2. Products
    • 10.2.7.3. SWOT Analysis
    • 10.2.7.4. Recent Developments
    • 10.2.7.5. Strategies
    • 10.2.7.6. Financials (Based on Availability)
  • 10.2.8. Sandoz International GmbH
    • 10.2.8.1. Overview
    • 10.2.8.2. Products
    • 10.2.8.3. SWOT Analysis
    • 10.2.8.4. Recent Developments
    • 10.2.8.5. Strategies
    • 10.2.8.6. Financials (Based on Availability)
  • 10.2.9. Par Pharmaceutical Companies Inc.
    • 10.2.9.1. Overview
    • 10.2.9.2. Products
    • 10.2.9.3. SWOT Analysis
    • 10.2.9.4. Recent Developments
    • 10.2.9.5. Strategies
    • 10.2.9.6. Financials (Based on Availability)
  • 10.2.10. Otsuka Holdings Co., Ltd.
    • 10.2.10.1. Overview
    • 10.2.10.2. Products
    • 10.2.10.3. SWOT Analysis
    • 10.2.10.4. Recent Developments
    • 10.2.10.5. Strategies
    • 10.2.10.6. Financials (Based on Availability)